INTRODUCTION TO LLS THERAPY ACCELERATION PROGRAM

April 2020
OUR MISSION

Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families

More than $1.3 billion invested in research

Unparalleled patient support and education services

Advocacy to accelerate cures and access
LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients.
Research by Funding Mechanism - FY19

- TRP 33%
- SCOR 21%
- CDP 19%
- TAP 13%
- Canada 6%
- Other 4%
- SLP 2%
- MCL 2%

$54.5 Million
Therapy Acceleration Program (TAP)

- Meeting LLS Mission is first priority
- Strategic initiative established in 2007
-Accelerate high-risk innovative blood cancer therapeutics
-Generating ROI to further fund LLS Mission is secondary
  - Biotech Accelerator: Co-fund up to 50%
  - Academic Clinical: Co-fund 50%+
Therapy Acceleration Program (TAP)
Venture Philanthropy Funding to Support Novel Therapies

- >$120M invested to date
- >60 projects
- 3 FDA-Approved Therapies
  - Vyxeos (AML)
  - Yescarta (DLBCL, tFL, PMBCL)
  - Elzonris (BPDCN)
- >20 assets in clinical development
  - 3 registration-enabling studies ongoing, 2 planned in 2020

www.lls.org/therapy-acceleration-program
<table>
<thead>
<tr>
<th>THERAPY</th>
<th>TARGET/MODALITY</th>
<th>INDICATION(S)</th>
<th>PRECLINICAL</th>
<th>PHASE I</th>
<th>PHASE II</th>
<th>PHASE II REG/PHASE III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magrolimab Combinations</td>
<td>Anti-CD47 Antibody</td>
<td>MDS</td>
<td></td>
<td></td>
<td></td>
<td>MDS (+Azac) DLBCL (+Ritux)</td>
</tr>
<tr>
<td>Cobomarsen</td>
<td>miR-155 Small Molecule</td>
<td>Cutaneous T-cell Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td>miRagen</td>
</tr>
<tr>
<td>AFM13 + Pembrolizumab</td>
<td>CD30/CD16A Bispecific Engager</td>
<td>Hodgkin Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td>affimed</td>
</tr>
<tr>
<td>Duvelisib + Romidepsin</td>
<td>PI3Kδ/γ Small Molecule</td>
<td>Peripheral T-cell Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td>Verastem Oncology</td>
</tr>
<tr>
<td>MILs</td>
<td>Cell Therapy</td>
<td>Post-transplant Myeloma</td>
<td></td>
<td></td>
<td></td>
<td>JOHNS HOPKINS MEDICINE</td>
</tr>
<tr>
<td>CPI-0610</td>
<td>BET Small Molecule</td>
<td>AML/MDS Lymphoma Myeloma</td>
<td></td>
<td></td>
<td></td>
<td>Constellation Pharmaceuticals</td>
</tr>
<tr>
<td>X4P-001 + Ibrutinib</td>
<td>CXCR4 Small Molecule</td>
<td>Waldenstrom Macroglobulinemia</td>
<td></td>
<td></td>
<td></td>
<td>X4 Pharmaceuticals</td>
</tr>
<tr>
<td>STRO-001</td>
<td>Anti-CD74 Antibody Drug Conjugate</td>
<td>Lymphoma Myeloma</td>
<td></td>
<td></td>
<td></td>
<td>SURTRO BIOPHARMA</td>
</tr>
<tr>
<td>SEL120</td>
<td>CDK8/19 Small Molecule</td>
<td>AML</td>
<td></td>
<td></td>
<td></td>
<td>RYU</td>
</tr>
<tr>
<td>NEXI-001</td>
<td>Cell Therapy</td>
<td>Post-transplant AML</td>
<td></td>
<td></td>
<td></td>
<td>NexImmune</td>
</tr>
<tr>
<td>NK cells + ALT-803</td>
<td>Cell Therapy</td>
<td>Heme Malignancies</td>
<td></td>
<td></td>
<td></td>
<td>Case Western Reserve University</td>
</tr>
<tr>
<td>CAR-37</td>
<td>Cell Therapy</td>
<td>B-cell NHL T-cell NHL</td>
<td></td>
<td></td>
<td></td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>PROTACs</td>
<td>IRAK4/STAT3 Small Molecule</td>
<td>Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td>Kymera</td>
</tr>
</tbody>
</table>

**Studies Actively Supported by TAP**
LLS TAP Funding Is Competitive
Clinical stage therapeutics in high unmet need indications

Average annual number
Target $2-6M dollars co-funding (equity purchase or contingent return agreement)
Typically 3-6 months to reach TAP Committee Review
LLS TAP Committee

- Subcommittee of LLS National Board
- Members consist of KOLs, IP lawyer, VC-investors in biotech, Industry veterans
- TAP Research performs S&E and recommends TAP projects to the Committee
- Company presents to the TAP Committee
- The Committee may approve, conditionally approve or reject company funding request
- Committee approval provides Research BD to proceed to Term Sheet and then formal Agreement
Key Criteria

- High Unmet Medical Need
- Innovative Science
- First-in-Class
- High potential to impact clinical practice
- Clinical PoC Study or Registration-Directed Study
- Strong IP Position
- Competent Management Team
- Solid Corporate Finance
Why Companies Come to TAP in addition to $$

- Deep knowledge of blood cancer landscape
- Expertise in hem/onc clinical development within LLS and via KOLs
- Connections to patients
- Advocacy efforts for patients
- Biotech companies leverage LLS approval to raise additional funds
- Track record of success
TAP Impact

- Deliver new and better treatments to patients
- Influence clinical practice for patient benefits
- Incentivize companies to study innovative & promising therapeutics in hematological indications in the clinic for PoC or regulatory approval
- Help attract more funding to TAP partners for them to continue development of promising therapeutics
- Generate monetary returns for LLS Mission
TAP is Bridging the Gap for Biotech

- Forty Seven
- Kite Pharma
- Celator Pharmaceuticals
- Acetylon Pharmaceuticals, Inc.
- Epizyme
- Avila Therapeutics
- Shape Pharmaceuticals
- Johns Hopkins Medicine
- Columbia University

- Gilead
- Jazz Pharmaceuticals
- Celgene
- Medivir
- WindMIL Therapeutics
- Lin BioScience
- KURA Oncology

BEATING CANCER IS IN OUR BLOOD.
We have one goal: A world without blood cancers

THANK YOU